This may be due to the fact that t-NEPC patients are already being treated for prostate cancer, and if PSA is low and the patient has no symptoms, imaging studies, NSE, ProGRP evaluation, and prostate rebiopsy may be delayed during the course of the disease. Here, ENO2 is linked to prostate cancer.